Levels of BCL2-related anti-apoptotic proteins are reported to be expressed at higher levels in CML LSCs compared with normal stem cells [116] and is further increased in acute phase. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.